Genmab stock advances as Q4 readouts stay on track

Genmab stock traded at DKK 2,244.00 on the primary Nasdaq Copenhagen market at 3:28 p.m. on September 22, 2026, while the shares were up 10.80 percent since January 1. Newsquawk reported on September 22, 2026, that three crucial clinical readouts remain on track for the fourth quarter of 2026.

Three readouts shape the catalyst

The Q4 2026 timetable gives Genmab a defined sequence of operating milestones rather than a single binary event. For investors, the timing matters because each readout can change expectations for the company's development pipeline and commercial prospects.

MarketScreener published a transcript dated September 22, 2026, covering Genmab's presentation at the Bank of America Global Healthcare Conference. The event places the pipeline update alongside direct management communication on the company's development programs.

Stock gains 10.80 percent in 2026

The DKK 2,244.00 reference price at 3:28 p.m. on September 22, 2026, compares with a 10.80 percent gain since the start of the year and a 4.47 percent increase over five trading days. That combination makes the scheduled Q4 milestones the clearest numerical reference point for the current share-price narrative.

The intraday quotation also showed a 0.71 percent decline at the cited time, illustrating the difference between the year's performance and the latest session. The market is therefore weighing a positive year-to-date return against short-term fluctuations while the three readouts approach.

Genmab stock remains tied to data

Genmab stock closed the cited market update at DKK 2,244.00 on September 22, 2026, on Nasdaq Copenhagen. The next material valuation signal is the outcome of the three Q4 2026 readouts, because the current market data already show a 10.80 percent year-to-date comparison.

More news and analyses on Genmab stock